Share the Video:

Compass Pathways: Update

PS2025

Steven Levine

Compass Pathways is pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of COMP360 psilocybin treatment, potentially a first in class treatment. The COMP360 program aims to evaluate the safety and efficacy of COMP360 psilocybin, a synthetic, proprietary formulation of psilocybin under investigation for difficult-to-treat mental health conditions. There are two pivotal phase 3 trials, COMP005 and COMP006, studying the efficacy of COMP360 for treatment-resistant depression (TRD). 

Become a MAPS Member with a monthly donation

As a Member, you’re not just making a donation — you’re joining a community that is at the forefront of advancing research, changing policy, and evolving education around psychedelics. Join us in shaping a future where these life-changing tools are available to those who need them most.

Compass Pathways: Update

Become a MAPS Member with a monthly donation

Related Videos

Stewarding Systems Change: Psychedelics, Leadership, and Collective Action

Between Ecstasy and Escapism: Raving as a Contemporary Ritual

atai Life Sciences pipeline update and development progress of BPL-003, VLS-01 and EMP-01 programs

Veterans’ Attitudes and Beliefs About the Therapeutic Use of Psychedelic Drugs

Preparing for the Fourth Drive: Raising Psychedelic-Savvy Teens

Life-threatening Illness, Palliative Care, and Psychedelics: Patients' Perspectives

Psychedelics in Deathwork: Crossing Thresholds

Compass Pathways: Update

The Rhythms of Connection: Psychedelics and the History of House Music